Barclays Maintains Overweight on 10x Genomics, Lowers Price Target to $24
10x Genomics +2.39% Pre
10x Genomics TXG | 15.86 15.86 | +2.39% 0.00% Pre |
Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:
TXG) with a Overweight and lowers the price target from $36 to $24.